Aragen Bioscience Inks License with Cevec | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.

The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.